Chief Business Officer, Sixfold Bioscience
Tina Flatau works with growing biopharma companies to establish and protect value in their core R&D, grow operational capabilities, and enable financing and partnering pre- and post-IPO /acquisition.
She has run operations and development programmes from R to D transition up to file. Previously as a consultant, she has developed and implemented operational effectiveness programmes across the whole R&D spectrum, from organizational start-ups to programme optimizations and improvements in the UK, Europe and the US with many of the big pharmas.
Tina is a pharmaceutical sciences PhD formerly with SmithKlineBeecham Pharmaceuticals, Coopers & Lybrand / PriceWaterhouse Coopers. She specialises in providing expert input to biotech companies from start-up and venture-capital stage to mid-sized companies at the stage of pharma collaborations and acquisition. Tina worked with specialist rare disease company Prosensa Therapeutics from 2009-2014, where she was VP of Alliances and Project Management, overseeing the R&D pipeline of antisense therapies and completing the business-side SEC submissions for Prosensa’s successful NASDAQ IPO in 2013. She has a special interest in orphan disease and rare disease patient advocacy. Tina is a Board member at Action Duchenne and a Research Ethics Committee member within the NHS.